Recent News

• 09.17.2025 - bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
• 09.09.2025 - Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
• 09.03.2025 - U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
• 08.18.2025 - bioAffinity Technologies Appoints New Members to Board of Directors
• 08.14.2025 - bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
• 08.14.2025 - bioAffinity Technologies Reports Second Quarter 2025 Results

Recent Filings

• 09.16.2025 - EFFECT Notice of Effectiveness
• 09.15.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 09.09.2025 - EX-99.1 EX-99.1
• 09.09.2025 - 8-K Current report
• 09.05.2025 - EX-99.1 EX-99.1
• 09.05.2025 - 8-K Current report
• 09.03.2025 - 8-K Current report
• 09.03.2025 - EX-99.1 EX-99.1
• 09.02.2025 - 8-K Current report
• 08.29.2025 - S-1 General form for registration of securities under the Securities Act of 1933